Highlighting the implications and innovations of clinical trial research to advance evidence-based medicine and public health.
- Tweets 49
- Following 1
- Followers 198
- Likes 0
馃挱 In your opinion, how many clinical trials that claim to be "pragmatic" are successful in providing useful evidence for real-world decision-making?
JAMA+ Trials wants to hear from you.
馃敆 Share your perspective: ja.ma/4iMBSQB
21
馃摙 JAMA+ Trials wants to hear from you.
Share your perspective in our latest poll and help spark discussion around the future of clinical trial research.
馃搳 Vote now: ja.ma/3TniYWb
21
馃摙 Share your opinion: How many clinical trials that claim to be "pragmatic" actually provide useful evidence for real-world decision-making?
馃搳 Vote now and join the discussion: ja.ma/4h5U1rm
#ClinicalTrials #Research #Evidence
37
How many clinical trials that claim to be "pragmatic" are successful in providing useful evidence for real-world decision-making?
馃挱 Cast your vote in the latest JAMA+ Trials Poll and share your perspective.
馃搳 Take the poll: ja.ma/4yMrE7l
1
45
馃挱 In your opinion, how many clinical trials that claim to be "pragmatic" are successful in providing useful evidence for real-world decision-making?
@JAMAplusTrials wants to hear from you.
馃敆 Vote now: ja.ma/4hhDAHf
2
111
Among infants with neonatal opioid withdrawal syndrome cared for with the #EatSleepConsole approach, symptom-based opioid dosing was associated with a shorter time to medical readiness for discharge than a scheduled opioid taper.
馃敆 ja.ma/3V5d8sV
ALT JAMA study: Symptom-based opioid dosing decreases time to medical readiness for infants with neonatal opioid withdrawal syndrome (NOWS). Population: 185 males, 198 females. Findings: symptom-based dosing 9.18 days vs. scheduled opioid taper 11.61 days.
1
50
馃摚 This JAMA+ Trials Theme of the Month examines how #pragmatic clinical trials are intended to generate evidence for real-world clinical decisions without sacrificing research rigor.
馃摤 Learn more about this trial and subscribe to the newsletter: ja.ma/3V60NES
20
馃挱 In your opinion, how many clinical trials that claim to be "pragmatic" are successful in providing useful evidence for real-world decision-making?
JAMA+ Trials wants to hear from you.
馃敆 Share your perspective: ja.ma/4rlS2T0
2
107
Among older surgical patients with #frailty, assignment to home-based prehabilitation before elective noncardiac surgery did not improve 30-day disability scores or reduce postoperative complications vs usual care.
馃敆 ja.ma/4ya0Jmj
1
37
馃摚 This JAMA+ Trials Theme of the Month examines how #pragmatic clinical trials are intended to generate evidence for real-world clinical decisions without sacrificing research rigor.
馃摤 Learn more about this trial and subscribe to the newsletter: ja.ma/4yOqd8s
16
Among veterans seeking primary care for #LowBackPain, a sequenced care pathway was not superior to a pain navigator pathway for improving pain interference or physical function at 3 months.
馃敆 ja.ma/3V0qYgg
1
1
59
馃摚 This month's JAMA+ Trials Theme of the Month examines how #pragmatic clinical trials are intended to generate evidence for real-world clinical decisions without sacrificing research rigor.
馃摤 Learn more and subscribe to the newsletter: ja.ma/4heZwnL
13
馃摙 Share your opinion: New JAMA+ Trials Poll!
How many clinical trials that claim to be "pragmatic" actually provide useful evidence for real-world decision-making?
馃搳 Vote now and join the discussion: ja.ma/4h5U1rm
#ClinicalTrials #Research #Evidence
6
3
2,416
Filgotinib lowered the risk of treatment failure in participants with active noninfectious intermediate uveitis, posterior uveitis, or panuveitis vs placebo.
ja.ma/4h6Uxpm
86
Among patients with stable #MultipleSclerosis, discontinuing first-line disease-modifying therapy was associated with recurrent inflammatory disease activity vs continuation, leading to early trial termination.
ja.ma/4yVnPOc
64
馃挰 Editorial: #Deescalation and discontinuation trials assess whether less care can achieve noninferior outcomes while reducing adverse effects, patient burden, and societal costs.
ja.ma/4fN0SUK
1
77
RCT: Zilucoplan, a complement inhibitor targeting C5, did not impact the progression in patients with amyotrophic lateral sclerosis (#ALS).
ja.ma/3TPzRZi
90
Looking for the latest practice-changing evidence?
Explore the JAMA+ Trials Theme of the Month, featuring a curated selection of clinical trials and research that highlight key developments in medicine.
ja.ma/4g6sl4W
1
57
RCT: Among preterm infants with PDA, expectant management vs pharmacologic closure showed no difference in the composite outcome of death or BPD at 36 weeks and a lower risk of mortality compared with pharmacologic treatment.
ja.ma/45BeYnc
ALT JAMA study: Among preterm infants (22-28 weeks gestation) with patent ductus arteriosus, expectant management vs active treatment didn't significantly decrease death or bronchopulmonary dysplasia. 244 male/237 female infants, median age 25 weeks. Expectant-80.9%, Active-79.6%.
1
1
97
JAMA+ Trials: In a RCT involving more than 1500 participants, investigators evaluated whether audiovisual enhancements to electronic consent increased consent rates or improved comprehension compared with text-only formats.
馃摉 From @JAMANetworkOpen: ja.ma/3QQDFsc
1
89
These findings offer new insights into participant engagement and the potential for multimedia consent interventions highlighted by JAMA+ Trials.
馃摤 Sign up for the JAMA+ Trials email newsletter: ja.ma/4w4wZWw
33